{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:59:23Z","timestamp":1768640363391,"version":"3.49.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.det.2018.12.003","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T02:33:32Z","timestamp":1550111612000},"page":"215-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Treatment Update of Autoimmune Blistering Diseases"],"prefix":"10.1016","volume":"37","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveed","family":"Sami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.det.2018.12.003_bib1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10083","key":"10.1016\/j.det.2018.12.003_bib4","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.det.2018.12.003_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2018.12.003_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.det.2018.12.003_bib7","doi-asserted-by":"crossref","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","author":"Salopek","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3389\/fimmu.2018.01189","article-title":"Reversing autoimmunity combination of rituximab and IVIg","volume":"9","author":"Ahmed","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.det.2018.12.003_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.det.2018.12.003_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2013.05.016","article-title":"Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids","volume":"69","author":"Almugairen","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.003_bib11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial","author":"Ng","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.det.2018.12.003_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A\u00a0comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2018.12.003_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2010.02.052","article-title":"Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission","author":"Strowd","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","author":"Amber","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2018.12.003_bib19","first-page":"1","article-title":"Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients","author":"Keeley","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2018.12.003_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2010.06.033","article-title":"Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris","author":"Craythorne","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib21","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-1746","article-title":"First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus","author":"Cho","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2018.12.003_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","author":"Ingen-Housz-Oro","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.det.2018.12.003_bib23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.01.020","article-title":"Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)","author":"Maley","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.01.046","article-title":"Treatment of mucous membrane pemphigoid with rituximab","author":"Heelan","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum b-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","author":"Hall","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7","key":"10.1016\/j.det.2018.12.003_bib28","first-page":"731","article-title":"Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab","volume":"6","author":"Taverna","year":"2007","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib29","doi-asserted-by":"crossref","DOI":"10.3315\/jdcr.2008.1007","article-title":"Rituximab therapy of recalcitrant bullous dermatoses","author":"Wollina","year":"2008","journal-title":"J\u00a0Dermatol Case Rep"},{"key":"10.1016\/j.det.2018.12.003_bib30","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-0560","article-title":"Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab","author":"Schumann","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2018.12.003_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-3083.2010.03889.x","article-title":"Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients","author":"Lourari","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2018.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","author":"Kasperkiewicz","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib33","doi-asserted-by":"crossref","DOI":"10.1517\/14712598.2015.1046833","article-title":"Rituximab preserves vision in ocular mucous membrane pemphigoid","author":"R\u00fcbsam","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.det.2018.12.003_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib35","doi-asserted-by":"crossref","first-page":"e12726","DOI":"10.1111\/dth.12726","article-title":"The use of rituximab in treatment of epidermolysis bullosa acquisita: three new cases and a review of the literature","author":"Bevans","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2018.12.003_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2007.07982.x","article-title":"Severe persistent pemphigoid gestationis: long-term remission with rituximab","author":"Cianchini","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.13962","article-title":"Pemphigoid gestationis: a successful preventive treatment by rituximab","author":"Tourte","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2018.12.003_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2016.4676","article-title":"Rituximab treatment for recalcitrant dermatitis herpetiformis","author":"Albers","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.003_bib39","first-page":"672","article-title":"Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature","volume":"12","author":"Shetty","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.003_bib40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1525-1470.2008.00751.x","article-title":"Severe bullous pemphigoid in an infant- successful treatment with rituximab","volume":"25","author":"Schulze","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2014.05.071","article-title":"Successful use of rituximab in the treatment of childhood and juvenile pemphigus","author":"Vinay","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib42","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/pde.12744","article-title":"Rituximab therapy for childhood pemphigus vulgaris","volume":"33","author":"Kincaid","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib43","doi-asserted-by":"crossref","DOI":"10.1159\/000287254","article-title":"Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature","author":"Fuertes","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2018.12.003_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bmt.1703654","article-title":"Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease","author":"Szabolcs","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.det.2018.12.003_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/j.1525-1470.2007.00369.x","article-title":"Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment","author":"Connelly","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/pde.12057","article-title":"Refractory childhood pemphigoid successfully treated with rituximab","author":"Fuertes","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib47","article-title":"Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG","author":"Aoyama","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/1744-9987.12536","article-title":"Bullous pemphigoid successfully treated with a combination therapy of plasmapheresis followed by intravenous high dose immunoglobulin","author":"Hattori","year":"2017","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.det.2018.12.003_bib49","article-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","author":"Shimanovich","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib50","article-title":"Treatment of severe pemphigus vulgaris of the scalp with adjuvant rituximab and immunoadsorption","author":"Kamphausen","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2011.10732.x","article-title":"Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris","author":"Behzad","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","article-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","volume":"166","author":"Kasperkiewicz","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","author":"Kolesnik","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"17","key":"10.1016\/j.det.2018.12.003_bib54","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.12.003_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","author":"Feldman","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.det.2018.12.003_bib57","first-page":"1","article-title":"Rituximab\/IVIG in pemphigus\u2014a 10-year study with a long follow-up","author":"Hamadah","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2018.12.003_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/ced.13092","article-title":"Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin","author":"Nguyen","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","author":"Ahmed","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. a preliminary report","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.det.2018.12.003_bib61","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0000000000001024","article-title":"Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis\u2014an interventional case series","author":"Steger","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.det.2018.12.003_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib63","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2013.8175","article-title":"Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score","author":"Rahbar","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16265","article-title":"An Oral Disease Severity Score validated for use in oral pemphigus vulgaris","author":"Ormond","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.12711","article-title":"Outcome measures for autoimmune blistering diseases","author":"Zhao","year":"2015","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib66","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"issue":"4","key":"10.1016\/j.det.2018.12.003_bib67","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","article-title":"Future therapies for pemphigus vulgaris: rituximab and beyond","volume":"74","author":"Huang","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/ijd.IJD_199_17","article-title":"Shifting focus in the therapeutics of immunobullous disease","volume":"62","author":"De","year":"2017","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.003_bib69","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2010.037390","article-title":"Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin\u2019s lymphoma","volume":"96","author":"Negrea","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.det.2018.12.003_bib70","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.003_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157961","article-title":"Safety of repeated open-label treatment courses of intravenous ofatumumab, a human anti-CD20 monoclonal antibody, in rheumatoid arthritis: results from three clinical trials","volume":"11","author":"Quattrocchi","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.det.2018.12.003_bib72","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.det.2018.12.003_bib73","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J\u00a0Exp Med"},{"issue":"9","key":"10.1016\/j.det.2018.12.003_bib74","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.det.2018.12.003_bib75","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.det.2018.12.003_bib76","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2006.04.004","article-title":"BAFF, APRIL and human B cell disorders","volume":"18","author":"Tangye","year":"2006","journal-title":"Semin Immunol"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris","volume":"155","author":"Asashima","year":"2006","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2018.12.003_bib78","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-Cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib79","first-page":"103","article-title":"Pemphigus vulgaris: approach to treatment","volume":"25","author":"Sinha","year":"2014","journal-title":"Eur J Dermatol"},{"issue":"6295","key":"10.1016\/j.det.2018.12.003_bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib81","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1523-1747.1998.00086.x","article-title":"Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals","volume":"110","author":"Hertl","year":"1998","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.003_bib82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/08916930500124429","article-title":"The role of T cells in cutaneous autoimmune disease","volume":"38","author":"Chow","year":"2005","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib83","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.jid.5700016","article-title":"Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model","volume":"126","author":"Aoki-Ota","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib84","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.4049\/jimmunol.181.2.1526","article-title":"Novel system evaluating in\u00a0vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris","volume":"181","author":"Takahashi","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"125","key":"10.1016\/j.det.2018.12.003_bib85","first-page":"1088","article-title":"An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus vulgaris","author":"Anhalt","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"issue":"25","key":"10.1016\/j.det.2018.12.003_bib86","doi-asserted-by":"crossref","first-page":"23778","DOI":"10.1074\/jbc.M501365200","article-title":"Desmosome signaling: inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization","volume":"280","author":"Berkowitz","year":"2005","journal-title":"J\u00a0Biol Chem"},{"issue":"34","key":"10.1016\/j.det.2018.12.003_bib87","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1073\/pnas.0602973103","article-title":"p38MAPK inhibition prevents disease in pemphigus vulgaris mice","volume":"103","author":"Berkowitz","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.12.010","article-title":"Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering","volume":"85","author":"Yoshida","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib89","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1074\/jbc.M110.172874","article-title":"p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris","volume":"286","author":"Mao","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.det.2018.12.003_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2006.058388","article-title":"Mitogen activated protein kinase inhibitors: where are we now and where are we going?","volume":"65","author":"Sweeney","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2018.12.003_bib91","doi-asserted-by":"crossref","first-page":"AB141","DOI":"10.1016\/j.jaad.2016.02.555","article-title":"A\u00a0new treatment for autoimmune blistering diseases - the efficacy of the Bruton\u2019s tyrosine kinase inhibitor PRN473 in canine pemphigus foliaceus","volume":"74","author":"Outerbridge","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib92","series-title":"GeneReviews","article-title":"X-linked agammaglobulinemia","author":"Smith","year":"2001"},{"key":"10.1016\/j.det.2018.12.003_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00370","article-title":"Soluble Fas ligand is essential for blister formation in pemphigus","volume":"9","author":"Lotti","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2018.12.003_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of FcRn in antigen presentation","author":"Baker","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2018.12.003_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","author":"Li","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.det.2018.12.003_bib97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/DDDT.S49409","article-title":"Omalizumab, an anti-immunoglobulin E antibody: state of the art","volume":"8","author":"Incorvaia","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib98","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and Fc\u025bRI on basophils","volume":"113","author":"Lin","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40261-015-0267-9","article-title":"Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience","volume":"35","author":"Romano","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"Van Beek","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib101","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","article-title":"IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases","volume":"12","author":"van Beek","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib102","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.det.2018.12.003_bib103","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.det.2018.12.003_bib104","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib105","first-page":"523","article-title":"Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200","volume":"60","author":"Yalcin","year":"2014","journal-title":"Clin Lab"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib106","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.det.2018.12.003_bib107","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib108","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000452828","article-title":"Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments","volume":"9","author":"Bilgi\u00e7 Temel","year":"2017","journal-title":"Case Rep Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib109","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2340\/00015555-2845","article-title":"Biological and clinical response to omalizumab in a patient with bullous pemphigoid","volume":"98","author":"Menzinger","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"10.1016\/j.det.2018.12.003_bib111","first-page":"1213","article-title":"Bertilimumab Cambridge Antibody Technology Group","volume":"5","author":"Ding","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.det.2018.12.003_bib112","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2249.2011.04464.x","article-title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid","volume":"166","author":"G\u00fcnther","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.det.2018.12.003_bib113","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","author":"Kridin","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib114","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2017.11.002","article-title":"The pharmacokinetics of fumaric acid esters reveal their in\u00a0vivo effects","volume":"39","author":"Mrowietz","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib116","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"issue":"6387","key":"10.1016\/j.det.2018.12.003_bib117","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.aan4665","article-title":"Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity","volume":"360","author":"Kornberg","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.det.2018.12.003_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01890","article-title":"The immunometabolomic interface receptor hydroxycarboxylic acid receptor 2 mediates the therapeutic effects of dimethyl fumarate in autoantibody-induced skin inflammation","volume":"9","author":"Wannick","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.det.2018.12.003_bib119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/JID.2015.361","article-title":"Dimethylfumarate impairs neutrophil functions","volume":"136","author":"M\u00fcller","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.12.003_bib120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.smim.2018.03.002","article-title":"The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin","volume":"37","author":"Sadik","year":"2018","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.det.2018.12.003_bib121","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","article-title":"The leukotriene B4and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita","volume":"137","author":"Sezin","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"25","key":"10.1016\/j.det.2018.12.003_bib122","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2174\/1568026616666160413141911","article-title":"Heat shock protein (HSP) drug discovery and development: targeting heat shock proteins in disease","volume":"16","author":"Shrestha","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"10.1016\/j.det.2018.12.003_bib123","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/exd.12476","article-title":"Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses","volume":"23","author":"Tukaj","year":"2014","journal-title":"Exp Dermatol"},{"issue":"23","key":"10.1016\/j.det.2018.12.003_bib124","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1182\/blood-2010-10-314609","article-title":"Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets","volume":"117","author":"Kasperkiewicz","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.det.2018.12.003_bib125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/exd.13335","article-title":"Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita","volume":"26","author":"Ludwig","year":"2017","journal-title":"Exp Dermatol"},{"issue":"7","key":"10.1016\/j.det.2018.12.003_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070496","article-title":"Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid","volume":"8","author":"Tukaj","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.det.2018.12.003_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009792","article-title":"Identification of gp96 as a novel target for treatment of autoimmune disease in mice","volume":"5","author":"Han","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.det.2018.12.003_bib128","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1002\/art.24047","article-title":"Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis","volume":"58","author":"Rice","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.det.2018.12.003_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","volume":"3","author":"Puri","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2018.12.003_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01558","article-title":"Therapeutic effect of a novel phosphatidylinositol-3-kinase \u03b4 inhibitor in experimental epidermolysis bullosa acquisita","volume":"9","author":"Koga","year":"2018","journal-title":"Front Immunol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:42:37Z","timestamp":1760006557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518311458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":128,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0733863518311458"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.12.003","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Update of Autoimmune Blistering Diseases","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}